← FDA DRUG APPROVALS

FDA NDA · NDA019323

TEMOVATE

Sponsor: FOUGERA PHARMS

APPLICATION
NDA019323
TYPE
NDA
ORIGINAL APPROVAL
1985-12-27
LATEST ACTION
2003-04-02
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

TEMOVATE · ReferenceDiscontinued
CLOBETASOL PROPIONATE 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · OINTMENT · TOPICAL

Approval history

2003-04-02Labeling · Supplement 19 · standard — Label ↗AP
1998-06-01Manufacturing (CMC) · Supplement 17 · standardAP
1996-11-15Manufacturing (CMC) · Supplement 16 · standard — Review ↗AP
1995-08-30Labeling · Supplement 11AP
1994-06-29Manufacturing (CMC) · Supplement 15 · standardAP
1994-06-07Manufacturing (CMC) · Supplement 14 · standardAP
1993-08-23Manufacturing (CMC) · Supplement 13 · standardAP
1993-03-05Manufacturing (CMC) · Supplement 12 · standardAP
1992-04-17Manufacturing (CMC) · Supplement 10 · standardAP
1989-12-07Labeling · Supplement 7AP
1989-12-07Labeling · Supplement 5AP
1989-12-07Labeling · Supplement 8AP
1987-08-13Manufacturing (CMC) · Supplement 6 · standardAP
1987-07-10Manufacturing (CMC) · Supplement 3 · standardAP
1987-04-09Manufacturing (CMC) · Supplement 2 · standardAP
1987-03-03Manufacturing (CMC) · Supplement 4 · standardAP
1985-12-27Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →